Artivion price target raised to $47 from $42 at Citizens JMP

Citizens JMP raised the firm’s price target on Artivion (AORT) to $47 from $42 and keeps an Outperform rating on the shares. The stock is up roughly 45% year to date, attributable to the company’s continued positive progress within both its dependable base business and higher-growth Aortic stent graft business, in conjunction with adjusted EBITDA and margin improvement, the analyst tells investors in a research note.